ACTIVE

Amyl Therapeutics

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result-2 M €+17,3 %over 1 year
Gross margin-365,9 k €+58,1 %over 1 year
Equity3,5 M €-36,2 %over 1 year
Workforce6,8 ETP+47,8 %over 1 year

Identity

Source · BCE/KBO

Amyl Therapeutics is a Private limited company incorporated in 2020. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Liège. It employs on average 6,8 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0758.775.372
Incorporation
26/11/2020
Legal form
Private limited company
Registered office
Boulevard de Patience et Beaujonc 3
4000 Liège · WallonieSee on map
Contributed capital
5 971 289,80 €
Latest accounts
31/12/2025
Average workforce
6,8 ETP
Joint committees (2)
  • 200
  • 200000
Signals
Solid equityPositive cashflowHealthy social debts

Financials

Source · NBB, 6 filings

Trend over 5 financial years

20252024202320222021
Income statement
Gross margin-365,9 k €-872,4 k €-674,4 k €-840,6 k €-875,1 k €
EBITDA-1 M €-1,4 M €-1,2 M €-1,1 M €-888,7 k €
Operating result-3,9 M €-3,9 M €-3,2 M €-2,3 M €-1,2 M €
Net result-2 M €-2,4 M €-1,7 M €-1,4 M €-999,7 k €
Balance sheet
Equity3,5 M €5,6 M €8 M €6,2 M €7,6 M €
Total assets7 M €8,4 M €9 M €6,7 M €8,7 M €
Cash616,7 k €2,3 M €3,1 M €1,5 M €3,6 M €
Debts3,3 M €2,7 M €965 k €493,9 k €1,1 M €
Other
Workforce6,8 ETP4,6 ETP–––

Valuation

Indicative valuation

As an indication, this company is worth

between 2,5 M€ and 5 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

6 active · 3 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Christopher MAC NAUGHTON
Director16/06/2026 → 01/06/2032
Kenneth BUCKFIRE
Director29/03/2021 → 01/06/2032
MERIEUX PARTICIPATIONS SASRepresented by CALENDA Valérie
Director16/06/2026 → 01/06/2032
NOSHAQ PARTNERS0808.219.836Represented by Hugues WALLEMACQ
Director29/03/2021 → 01/06/2032
Swissvention Partners GMBH0734.792.024Represented by GROS FLORENT
Directorsince 26/11/2020
VACCIBIO CONSULTING0568.548.672Represented by Pierre Vandepapelière
Directorsince 26/11/2020

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
NOSHAQ0426.624.509Represented by Amel Tounsi
Director29/03/2021 → 2021 accounts
Valérie CALENDA
Director29/03/2021 → 2024 accounts
Swissvention Partners GMBHRepresented by Florent GROS
Director26/11/2020 → 2022 accounts

Other companies at this address

Boulevard de Patience et Beaujonc 3 4000 Liège
CompanyCBE no.
Abscint● Active
0749.828.410
Aeroforge● Active
1044.274.185
AMPACIMON● Active
0827.990.317
BECARV● Bankrupt
0840.777.885
BE.SPINE● Active
1013.110.857
CATALYA● Active
0727.648.171
CEFALY Technology● Active
0870.578.661
DERMAX● Active
0667.730.677
DIANOSIC● Active
1034.558.646
DW Cefaly Holding● Active
0725.837.241
EARTH ALIVE CLEAN TECHNOLOGIES BELGIUM● Active
1023.778.481
EXO Biologics● Active
0732.982.379
ExoXpert● Active
1003.807.666
EYED PHARMA● Active
0508.599.605
Hirundo Biosciences● Active
0681.855.065
HolyFox Invest● Active
1010.693.181
Hyloris● Active
0669.738.676
Hyloris Developments● Active
0542.737.368
Hyloris Pharmaceuticals● Active
0674.494.151
Hyloris Therapeutics● Active
1025.029.385

Full financial information

Source · NBB
20252024202320222021
Type of accountAbridged modelAbridged modelMicro modelMicro modelMicro model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/11/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/2021
Length of the financial year12 months12 months12 months12 months14 months
Filing date22/07/202602/07/202505/06/202403/07/202303/07/2023
General meeting16/06/202613/06/202504/06/202421/06/202316/05/2023
Currency of the financial yearEUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for free

Annual accounts filings

Source · NBB, 6 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202516/06/202622/07/2026FrenchPDF
Abridged model31/12/202413/06/202502/07/2025FrenchPDF
Micro model31/12/202304/06/202405/06/2024FrenchPDF
Micro model31/12/202221/06/202303/07/2023FrenchPDF
Micro modelCorrection31/12/202116/05/202303/07/2023FrenchPDF
Micro model31/12/202107/06/202229/08/2022FrenchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 2,5 M€ and 5 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

6 active · 3 ended

Active mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
Christopher MAC NAUGHTON
Director16/06/2026 → 01/06/2032
Kenneth BUCKFIRE
Director29/03/2021 → 01/06/2032
MERIEUX PARTICIPATIONS SASRepresented by CALENDA Valérie
Director16/06/2026 → 01/06/2032
NOSHAQ PARTNERS0808.219.836Represented by Hugues WALLEMACQ
Director29/03/2021 → 01/06/2032
Swissvention Partners GMBH0734.792.024Represented by GROS FLORENT
Directorsince 26/11/2020
VACCIBIO CONSULTING0568.548.672Represented by Pierre Vandepapelière
Directorsince 26/11/2020

Ended mandates

DirectorMandates in this companyPeriodOther mandatescurrentendedstruck offbankruptcies
NOSHAQ0426.624.509Represented by Amel Tounsi
Director29/03/2021 → 2021 accounts
Valérie CALENDA
Director29/03/2021 → 2024 accounts
Swissvention Partners GMBHRepresented by Florent GROS
Director26/11/2020 → 2022 accounts

Ownership and network

Looking for more information about this company?

Try for free

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Mandates22/07/2026
    DEMISSIONS, NOMINATIONS
    PDF
  • Capital / shares22/12/2025
    CAPITAL, ACTIONS
    PDF
  • Capital / shares04/02/2025
    CAPITAL, ACTIONS - DIVERS
    PDF
  • Registered office14/05/2024
    SIEGE SOCIAL
    PDF
  • Capital / shares12/02/2024
    DIVERS - CAPITAL, ACTIONS
    PDF
  • Capital / shares12/09/2023
    CAPITAL, ACTIONS
    PDF
  • Capital / shares12/04/2023
    CAPITAL, ACTIONS
    PDF
  • Mandates04/04/2023
    DEMISSIONS, NOMINATIONS
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

Source · CBE, NBB annual accounts
Year
Identity
Incorporation
Name
Registered office
Annual accounts
Filings5 filings
Mandates
NOSHAQ PARTNERS
MERIEUX PARTICIPATIONS SAS
Kenneth BUCKFIRE
Christopher MAC NAUGHTON
VACCIBIO CONSULTING
Swissvention Partners GMBH
NOSHAQ
Valérie CALENDA
Swissvention Partners GMBH
2020202120222023202420252026202720282029203020312032
Amyl Therapeutics
Boulevard de Patience et Beaujonc 3, 4000 LiègeRUE DEL RODGE CINSE 98, 4100 Seraing
Director
Director
Director
Director
Director
Director
Director
Director
CurrentPlanned, not yet servedEndedAccounts filedToday

Registered offices

Source · NBB annual accounts, CBE
Registered addressPeriodSource
Boulevard de Patience et Beaujonc 3, 4000 LiègeCurrent
accounts 2023 → 2025
Accounts 2025 · 2026-00345425
RUE DEL RODGE CINSE 98, 4100 Seraing
accounts 2021 → 2022
Accounts 2022 · 2023-00198732

Company names

Source · NBB annual accounts, CBE
NamePeriodSource
Amyl TherapeuticsCurrent
accounts 2021 → 2025
Accounts 2025 · 2026-00345425

Events

  1. 2025
    Annual accounts 2025-2 M €↑
  2. 2024
    Annual accounts 2024-2,4 M €↓
  3. 2023
    Annual accounts 2023-1,7 M €↓
  4. 2022
    Annual accounts 2022-1,4 M €↓
  5. 2021
    Annual accounts 2021-999,7 k €
  6. 26/11/2020
    IncorporationPrivate limited company